immunohistochemistry ihc data (Human Protein Atlas)
86
Structured Review
Human Protein Atlas
immunohistochemistry ihc data
Immunohistochemistry Ihc Data, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/immunohistochemistry+ihc+data/data+immunohistochemistry/pmc13282948-121-0-5
Average 86 stars, based on 1 article reviews
Immunohistochemistry Ihc Data, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/immunohistochemistry+ihc+data/data+immunohistochemistry/pmc13282948-121-0-5
Average 86 stars, based on 1 article reviews
immunohistochemistry ihc data - by Bioz Stars,
2026-10
86/100 stars
Images
1) Product Images from "ERO1A as a novel biomarker for risk stratification and immunotherapeutic guidance in early-stage lung adenocarcinoma"
Article Title: ERO1A as a novel biomarker for risk stratification and immunotherapeutic guidance in early-stage lung adenocarcinoma
Journal: PeerJ
doi: 10.7717/peerj.21347
Figure Legend Snippet: (A) Pan-cancer analysis of ERO1A expression between tumor and normal (or primary and metastatic) tissues from the TIMER database. (B) ERO1A expression in LUAD and normal tissues based on TCGA and GTEx data (GEPIA). *** P < 0.001; unpaired Student’s t-test. (C) Representative immunohistochemical (IHC) staining images of ERO1A in normal and LUAD tissues from the Human Protein Atlas (HPA) database. (D) ERO1A protein expression in normal lung tissues and LUAD tissues based on the HPA database. (E, F) Survival analysis (GEPIA) of ERO1A expression in TCGA-LUAD: (E) overall survival (OS, P < 0.001), (F) disease-free survival (DFS, P = 0.018). (G) ERO1A mRNA expression in TCGA-esLUAD tumors ( n = 233) vs normal tissues ( n = 32). *** P < 0.001; unpaired t-test. (H) Receiver operating characteristic (ROC) curve evaluating the performance of ERO1A expression in discriminating tumor from normal tissue (AUC = 0.988). (I, J) Kaplan-Meier survival analysis in TCGA-esLUAD based on ERO1A expression: (I) OS ( P = 0.007), (J) relapse-free survival (RFS, P = 0.004); log-rank test. (K, L) Time-dependent ROC (tROC) curves predicting (K) OS and (L) RFS at 1, 2, and 3 years in the TCGA-esLUAD cohort. (M) Kaplan-Meier analysis of OS in the GSE72094 esLUAD cohort stratified by ERO1A expression. *** P < 0.001; log-rank test. (N) ERO1A expression between alive ( n = 144) and deceased ( n = 77) patients in the GSE72094 esLUAD cohort. *** P < 0.001; unpaired t-test. (O) Representative images of ERO1A IHC staining in our institutional cohort of esLUAD tissue sections ( n = 90); right panel shows a magnified view of the region indicated by the box. Scale bar: 200 μm. (P) DFS analysis based on ERO1A high/low expression groups defined by IHC H-Score from our cohort. P = 0.002, log-rank test. (Q) Comparison of ERO1A H-Score between patients with ( n = 8) and without ( n = 82) DFS events. P = 0.008; Mann-Whitney U test. Abbreviations: esLUAD, early-stage lung adenocarcinoma; TIMER, tumor immune estimation resource; LUAD, lung adenocarcinoma; TCGA, the cancer genome atlas; GTEx, genotype-tissue expression; GEPIA, gene expression profiling interactive analysis; IHC, immunohistochemistry; HPA, human protein atlas; OS, overall survival; DFS, disease-free survival; ROC, receiver operating characteristic; AUC, area under the curve; RFS, relapse-free survival; tROC, time-dependent receiver operating characteristic; H-score, histochemistry score. *** P < 0.001; ** P < 0.01; * P < 0.05; ns, not significant.
Techniques Used: Expressing, Immunohistochemical staining, Immunohistochemistry, Comparison, MANN-WHITNEY, Gene Expression
Related Articles
Immunohistochemistry:Article Title: ERO1A as a novel biomarker for risk stratification and immunotherapeutic guidance in early-stage lung adenocarcinoma Article Snippet: .. Article Title: Integrative multimodal transcriptomics identifies a cancer-associated fibroblast membrane signature for predicting prognosis and therapeutic response in pancreatic ductal adenocarcinoma Article Snippet: .. To assess the protein-level expression of PaFMS signature genes, Article Title: Integrate single-cell and transcriptome analyses to explore the prognostic genes related to TRPM4 in bladder cancer Article Snippet: .. To validate the protein expression of prognostic genes, Article Title: USP48 promotes tumour progression through the deubiquitination and stabilization of DBF4 in clear cell renal carcinoma. Article Snippet: .. Their protein expression was then further validated by Article Title: Role of PTK6 in the diagnosis, prognosis, and immune infiltration of pancreatic cancer based on evidence from bioinformatics analysis and experimental validation. Article Snippet: .. Protein-level expression of PTK6 in pancreatic cancer was assessed using Article Title: Role of PTK6 in the diagnosis, prognosis, and immune infiltration of pancreatic cancer based on evidence from bioinformatics analysis and experimental validation. Article Snippet: .. To validate our transcriptomic findings at the protein level, we first examined PTK6 expression using Article Title: Establishment and validation of a prognostic model for pancreatic cancer utilizing genes of tumor-associated neutrophils. Article Snippet: .. The Article Title: Identification of plasma exosome circRNA as potential novel biomarkers for DLBCL and circrna-miRNA-mRNA network analysis Article Snippet: .. Additionally, protein-level expression patterns in normal and DLBCL tissues were comparatively evaluated using Staining:Article Title: ERO1A as a novel biomarker for risk stratification and immunotherapeutic guidance in early-stage lung adenocarcinoma Article Snippet: .. Article Title: Integrate single-cell and transcriptome analyses to explore the prognostic genes related to TRPM4 in bladder cancer Article Snippet: .. To validate the protein expression of prognostic genes, Expressing:Article Title: Integrative multimodal transcriptomics identifies a cancer-associated fibroblast membrane signature for predicting prognosis and therapeutic response in pancreatic ductal adenocarcinoma Article Snippet: .. To assess the protein-level expression of PaFMS signature genes, Article Title: Integrate single-cell and transcriptome analyses to explore the prognostic genes related to TRPM4 in bladder cancer Article Snippet: .. To validate the protein expression of prognostic genes, Article Title: USP48 promotes tumour progression through the deubiquitination and stabilization of DBF4 in clear cell renal carcinoma. Article Snippet: .. Their protein expression was then further validated by Article Title: Role of PTK6 in the diagnosis, prognosis, and immune infiltration of pancreatic cancer based on evidence from bioinformatics analysis and experimental validation. Article Snippet: .. Protein-level expression of PTK6 in pancreatic cancer was assessed using Article Title: Role of PTK6 in the diagnosis, prognosis, and immune infiltration of pancreatic cancer based on evidence from bioinformatics analysis and experimental validation. Article Snippet: .. To validate our transcriptomic findings at the protein level, we first examined PTK6 expression using Article Title: Establishment and validation of a prognostic model for pancreatic cancer utilizing genes of tumor-associated neutrophils. Article Snippet: .. The Article Title: Identification of plasma exosome circRNA as potential novel biomarkers for DLBCL and circrna-miRNA-mRNA network analysis Article Snippet: .. Additionally, protein-level expression patterns in normal and DLBCL tissues were comparatively evaluated using Membrane:Article Title: Integrative multimodal transcriptomics identifies a cancer-associated fibroblast membrane signature for predicting prognosis and therapeutic response in pancreatic ductal adenocarcinoma Article Snippet: .. To assess the protein-level expression of PaFMS signature genes, |